Benjamin Black Weighs Shift in U.S.A.I.D. Funding

XRP (CRYPTO: XRP) experienced a notable 43% gain over 30 days ending July 29, but seasoned investors anticipate a pullback is inevitable, questioning its timing and depth. Key factors may soon trigger this correction, though past dips in XRP often appear as opportunities rather than failures, suggesting underlying strength in its long-term investment thesis. Want More Context? 🔎

Seacor Marine (NYSE:SMHI) reported Q2 2025 results on July 30, revealing GAAP revenue of $60.8 million, missing expectations by 12.3%, while its GAAP loss per share of $(0.26) was slightly better than anticipated. The company's operating revenue declined by 13.0% year-over-year due to high repair expenses, although ongoing fleet modernization efforts showed some sequential improvements. Want More Context? 🔎

Shares of Micron Technology (NASDAQ: MU) fell 5.2% on Thursday morning, primarily due to issues attributed to Samsung, rather than any specific actions by Micron itself. The decline highlights the interconnected nature of the semiconductor industry and how external factors can significantly impact stock performance. Want More Context? 🔎

Lenz Therapeutics (NASDAQ:LENZ) reported second quarter 2025 results on July 30, revealing $5.0 million in GAAP revenue from licensing milestones, significantly surpassing analyst expectations. Despite a deeper net loss due to increased spending, the company made strides in its commercial plans ahead of an important FDA decision for its lead product, LNZ100, aimed at treating presbyopia. Want More Context? 🔎

Bitcoin (CRYPTO: BTC) and XRP (CRYPTO: XRP) have experienced significant pullbacks after a period of strong growth, with XRP dropping nearly 20% in one session and Bitcoin retreating after hitting a record high in July. Despite concerns that the summer rally might be over, these pullbacks are considered typical in a bull market, suggesting they are just temporary pauses rather than a sign of a trend reversal. Want More Context? 🔎

Wave Life Sciences (NASDAQ:WVE) reported disappointing Q2 2025 earnings, with revenue of $8.7 million falling short of the $13.2 million forecast and a loss per share of $0.31 versus the anticipated $0.28. Despite a 55.8% year-over-year revenue decline and increased operating expenses, the company made progress in its RNA-based medicine pipeline using its proprietary PRISM platform. Want More Context? 🔎